NASDAQ:RXDX

Prometheus Biosciences (RXDX) Price Target & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $199.60
▼
$199.98
50-Day Range: $192.50
▼
$199.92
52-Week Range: $23.27
▼
$199.98

Volume: 1.86 million shs
Average Volume: 913,102 shs
Market Capitalization: $9.56 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $162.70

Prometheus Biosciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 10 Analyst Ratings

Consensus Analyst Price Target

$162.70
-18.62% Downside

High Prediction	$200.00
Average Prediction	$162.70
Low Prediction	$111.00

Type	Current 9/27/22 to 9/27/23	1 Month Ago 8/28/22 to 8/28/23	3 Months Ago 6/29/22 to 6/29/23	1 Year Ago 9/27/21 to 9/27/22
Consensus Rating	Hold	Hold	Hold	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	10 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$162.70	$162.70	$153.36	$60.10
Predicted Upside	-18.62% Downside	33.84% Upside	35.37% Upside	45.58% Upside

Get Prometheus Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RXDX and its competitors with MarketBeat's FREE daily newsletter.

RXDX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RXDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Prometheus Biosciences Stock vs. The Competition

Type	Prometheus Biosciences	Medical Companies	S&P 500
Consensus Rating Score	2.30	2.66	2.49
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	-18.62% Downside	1,379.84% Upside	697.64% Upside
News Sentiment Rating	Positive News	Neutral News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
5/10/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$160.00 ➝ $200.00	+2.88%
4/18/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight
4/18/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform
4/17/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral
4/17/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
4/17/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$225.00 ➝ $200.00	+75.42%
4/16/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$155.00 ➝ $200.00	+75.42%
3/1/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$125.00 ➝ $150.00	+22.56%
1/31/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$117.00 ➝ $144.00	+26.69%
12/8/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$74.00 ➝ $181.00	+88.94%

(Data available from 9/27/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

RXDX Price Target - Frequently Asked Questions

What is Prometheus Biosciences's consensus rating and price target?: According to the issued ratings of 10 analysts in the last year, the consensus rating for Prometheus Biosciences stock is Hold based on the current 7 hold ratings and 3 buy ratings for RXDX. The average twelve-month price prediction for Prometheus Biosciences is $162.70 with a high price target of $200.00 and a low price target of $111.00. Learn more on RXDX's analyst rating history.
Do Wall Street analysts like Prometheus Biosciences more than its competitors?: Analysts like Prometheus Biosciences less than other Medical companies. The consensus rating for Prometheus Biosciences is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how RXDX compares to other companies.
Does Prometheus Biosciences's stock price have much upside?: According to analysts, Prometheus Biosciences's stock has a predicted upside of 33.84% based on their 12-month price targets.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:RXDX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Prometheus Biosciences (RXDX) Price Target & Analyst Ratings

Prometheus Biosciences Consensus Rating and Price Target (2023)

Consensus Analyst Rating

Consensus Analyst Price Target

RXDX Analyst Ratings By Month

RXDX Price Targets by Month

Prometheus Biosciences Stock vs. The Competition

Historical Target Prices and Ratings

RXDX Price Target - Frequently Asked Questions

Stock Ratings Reports and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info